Wildfire smoke is associated with worse survival for individuals with non–small cell lung cancer (NSCLC) who are recovering from surgical resection treatment.
Sandip Patel, MD, shares his expert perspectives on novel combination consolidation immunotherapy regimens that are under evaluation in unresectable early-stage NSCLC.
Conclusions from the first interim analysis of overall survival in the IMpower010 trial of adjuvant atezolizumab for non–small cell lung cancer has been met with some pushback.
Expert panelists discuss the characterization of patients with unresectable, early-stage NSCLC and what their standard treatment approach is for this patient population.
Researchers recommend staging laparoscopy for most patients with localized pancreatic ductal adenocarcinoma prior to resection to determine the stage of cancer and metastatic disease.